

Yong-Chen Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2526780/publications.pdf>

Version: 2024-02-01

39
papers

9,646
citations

257101

24
h-index

395343

33
g-index

41
all docs

41
docs citations

41
times ranked

13161
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. <i>Science</i> , 2022, 375, 877-884.	6.0	156
2	Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients. <i>Frontiers in Microbiology</i> , 2022, 13, 882520.	1.5	1
3	Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. <i>Cancer Immunology Research</i> , 2022, 10, 932-946.	1.6	52
4	Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 689091.	2.2	16
5	Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing. , 2021, 9, e002595.		31
6	Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma. , 2021, 9, e002882.		13
7	Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. <i>Cancers</i> , 2021, 13, 4334.	1.7	20
8	Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed. <i>Frontiers in Immunology</i> , 2021, 12, 645299.	2.2	9
9	Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy. <i>Cancers</i> , 2021, 13, 6061.	1.7	5
10	Harnessing the power of the immune system in cancer immunotherapy and cancer prevention. <i>Molecular Carcinogenesis</i> , 2020, 59, 675-678.	1.3	5
11	<i>Immunology of Melanoma</i> . , 2020, , 41-72.		0
12	Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy. <i>Cancer Immunology Research</i> , 2019, 7, 1824-1836.	1.6	40
13	Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. <i>Nature Communications</i> , 2019, 10, 449.	5.8	118
14	Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 534-543.	1.6	100
15	Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. <i>Journal of Immunology</i> , 2019, 202, 3458-3467.	0.4	36
16	Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. <i>Journal of Immunotherapy</i> , 2019, 42, 126-135.	1.2	231
17	<i>Immunology of Melanoma</i> . , 2019, , 1-32.		0
18	An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. <i>Molecular Therapy</i> , 2018, 26, 379-389.	3.7	78

#	ARTICLE	IF	CITATIONS
19	Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. <i>Nature Medicine</i> , 2018, 24, 724-730.	15.2	637
20	Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4347-4353.	3.2	26
21	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. <i>Journal of Clinical Oncology</i> , 2017, 35, 3322-3329.	0.8	204
22	Abstract 4982: Regression of metastatic breast cancer after adoptive cell transfer of tumor infiltrating lymphocytes and checkpoint blockade. , 2017, , .		0
23	T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2255-2262.	13.9	1,033
24	Targeting neoantigens for cancer immunotherapy: Table 1.. <i>International Immunology</i> , 2016, 28, 365-370.	1.8	42
25	Isolation and Characterization of an HLA-DPB1*04:01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. <i>Journal of Immunotherapy</i> , 2016, 39, 191-201.	1.2	27
26	Cancer immunotherapy targeting neoantigens. <i>Seminars in Immunology</i> , 2016, 28, 22-27.	2.7	199
27	Abstract CT003: A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer. , 2016, , .		0
28	Immunogenicity of somatic mutations in human gastrointestinal cancers. <i>Science</i> , 2015, 350, 1387-1390.	6.0	639
29	Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. <i>Science</i> , 2014, 344, 641-645.	6.0	1,460
30	The hepatitis B virus e antigen suppresses the respiratory burst and mobility of human monocytes and neutrophils. <i>Immunobiology</i> , 2014, 219, 880-887.	0.8	10
31	Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions. <i>Clinical Cancer Research</i> , 2014, 20, 3401-3410.	3.2	364
32	Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. <i>Journal of Immunology</i> , 2013, 190, 6034-6042.	0.4	145
33	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. <i>Nature Medicine</i> , 2013, 19, 747-752.	15.2	979
34	Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. <i>Blood</i> , 2012, 119, 5688-5696.	0.6	176
35	Crucial role for TNF receptor-associated factor 2 (TRAF2) in regulating NF- κ B signaling that contributes to autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18354-18359.	3.3	42
36	Rel phenocopies PKC δ , but not Bcl-2 in regulating CD8 ⁺ T cell activation versus tolerance. <i>European Journal of Immunology</i> , 2010, 40, 867-877.	1.6	9

#	ARTICLE	IF	CITATIONS
37	Differential Role for c-Rel and C/EBP β in TLR-Mediated Induction of Proinflammatory Cytokines. <i>Journal of Immunology</i> , 2009, 182, 7212-7221.	0.4	94
38	LPS/TLR4 signal transduction pathway. <i>Cytokine</i> , 2008, 42, 145-151.	1.4	2,424
39	C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. <i>Nature</i> , 2007, 446, 203-207.	13.7	224